Brief Description
This is a phase-2 clinical study, which means it tests whether a new medicine in a small group of people with a specific illness works well and is safe before larger studies are done. It comes usually comes after Phase 1, which checks basic safety of the drug in humans. This study will use the drug called N-Acetyl-D-Mannosamine (ManNAc) in patients with a disease called primary FSGS at a dose of 2g by mouth twice a day during a period of 12 weeks.
Trial Physician / Study Coordinator
Anirban Ganguli
Estimated Enrollment
15
Estimated End Date
July 2028
Trial is for people with
Primary Focal Segmental Glomerulosclerosis (FSGS)
Study Goal
This study wants to learn more about how the new drug ManNAc works in the body, how much of it stays in the body at different times, ...
What is involved for the patient?
Patients in this study will be asked to let the researchers look at their medical records, past medications, and kidney biopsy ...
About the drug or intervention
The medicine used in this study is called N-Acetyl-D-Mannosamine, or ManNAc for short. ManNAc is a type of sugar, but it’s not like ...